Patient Protection and Innovative Biologic Medicines Act of 2007
Latest action · Apr 20, 2007 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 19, 2007
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Patient Protection and Innovative Biologic Medicines Act of 2007 - Amends the Public Health Service Act to allow any person to submit an application for approval of a biologics license for a biological product that is claimed to be similar to a qualified biological product (reference product) after 12 years have elapsed since the reference product was approved or licensed.
Allows the Secretary of Health and Human Services to approve such a similar biological product: (1) only if the applicant demonstrates that the product conforms to the applicable final product-class specific guidance and the Secretary concludes the product is safe, pure, and potent; (2) only for indications for which the reference product is approved; and (3) to be effective only after at least 14 years have elapsed since the reference product was approved or licensed.
Prohibits the Secretary from designating a similar biological product as therapeutically equivalent to the reference product.
Prohibits the Secretary from approving a product that is claimed to be similar to or the same as a reference product under any other provision of law.
Authorizes any person to request issuance of product-class specific guidance applicable to a qualified biological product and its class.
Requires the Secretary to establish a Similar Biological Products Advisory Committee.
Sets forth provisions governing the naming of biotechnology-derived therapeutic protein and other biological products. Amends the Federal Food, Drug, and Cosmetic Act to deem a biotechnology-derived therapeutic protein to be misbranded if its labeling fails to meet the requirements of this Act.
Cosponsors 25
Members who signed on, in the order they did. Signatures ran from Apr 19, 2007 to Sep 23, 2008; 2 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-TX | Gene Green | Original | Apr 19, 2007 |
| D-WI | Tammy Baldwin | Original | Apr 19, 2007 |
| D-NY | Edolphus Towns | May 1, 2007 | |
| D-NC | G. K. Butterfield | May 9, 2007 | |
| D-WA | Adam Smith | May 17, 2007 | |
| D-AL | Artur Davis | May 17, 2007 | |
| D-WI | Ron Kind | May 17, 2007 | |
| D-CA | Ellen O. Tauscher | May 21, 2007 | |
| D-NY | Joseph Crowley | May 21, 2007 | |
| D-NY | Gregory W. Meeks | May 24, 2007 | |
| D-LA | Charlie Melancon | Jun 25, 2007 | |
| D-NY | Timothy H. Bishop | Jun 28, 2007 | |
| D-VA | James P. Moran | Jul 17, 2007 | |
| D-OR | Darlene Hooley | Jul 31, 2007 | |
| D-IN | Baron P. Hill | Sep 25, 2007 | |
| D-CA | Laura Richardson | Jan 29, 2008 | |
| D-IN | André Carson | Apr 29, 2008 | |
| D-PA | Patrick J. Murphy | May 15, 2008 | |
| D-PA | Joe Sestak | Jun 3, 2008 | |
| R-TX | Ron Paul | Jun 3, 2008 | |
| D-WI | Steve Kagen | Jul 31, 2008 | |
| D-CA | Joe Baca | Sep 9, 2008 | |
| D-PA | Christopher P. Carney | Sep 23, 2008 | |
| D-GA | John Barrow | Sep 23, 2008 | |
| D-TX | Ruben Hinojosa | Sep 23, 2008 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Apr 19, 2007 |
| Health Subcommittee | Referred Apr 20, 2007 |
Actions 3
Everything that happened, newest first.
- Apr 20, 2007Referred to the Subcommittee on Health.
- Apr 19, 2007Introduced in House
- Apr 19, 2007Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Printed hearings 2
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 110-187 | BUSINESS ACTIVITY TAX SIMPLIFICATION ACT OF 2008237 pages | Judiciary Committee | Jun 24, 2008 |
| Serial No. 110-40 | ASSESSING THE IMPACT OF A SAFE AND EQUITABLE BIOSIMILAR POLICY IN THE UNITED STATES190 pages | Energy and Commerce Committee | May 2, 2007 |
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| RL34045 | FDA Regulation of Follow-On Biologics Archived | Report | Apr 26, 2010 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Public Health Service Act to provide for the approval of similar biological products, and for other purposes.
- Short Titles as Introduced
- Patient Protection and Innovative Biologic Medicines Act of 2007
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Apr 19, 2007Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.